Quick Answer
ArriVent BioPharma, Inc. reported Stockholders Equity of $307.22 million for fiscal year 2025.
ArriVent BioPharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $307.22M | +19.2% |
| 2024 | $257.65M | +268.2% |
| 2023 | -$153.19M | -80.0% |
| 2022 | -$85.11M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $305.00M | +9.9% | +22.1% |
| June 30, 2025 | $249.87M | -15.8% | +23.4% |
| March 31, 2025 | $202.54M | -36.3% | -21.4% |
| December 31, 2024 | $257.65M | +268.2% | -7.1% |
| September 30, 2024 | $277.49M | +309.3% | -6.5% |
| June 30, 2024 | $296.66M | +350.4% | -6.6% |
| March 31, 2024 | $317.72M | +427.2% | +307.4% |
| December 31, 2023 | -$153.19M | -80.0% | -15.5% |
- ArriVent BioPharma, Inc. showed an increase of +19.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, ArriVent BioPharma, Inc.’s stockholders equity has grown by 461.0% (from -$85.11 million to $307.22 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: